OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc. (RPHM) priced its initial public offering on Apr 9, 2021 at $15.00 per share, within its $15.00–$17.00 range, raising $93.8M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $363.2M. Cooley advised the company and Latham & Watkins advised the underwriters.

At its 2021 IPO, Reneo Pharmaceuticals (now OnKure Therapeutics) was a clinical-stage pharmaceutical company developing REN001, a selective PPAR delta agonist, for patients with rare genetic mitochondrial diseases, including primary mitochondrial myopathies, which impair the cell's ability to produce energy.

Status

IPO

Ticker

RPHM

Exchange

Nasdaq Global Market

Priced

Apr 9, 2021

IPO price

$15.00

Price range

$15.00–$17.00

Raised

$93.8M

Market cap at IPO price

$363.2M

First filed

Mar 19, 2021

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CO

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.